GlassScriptPhysician profile
Henry B Kaplan
NPI 1003983719
$13,166.56
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,598 · 2020: $408 · 2021: $2,205 · 2022: $876 · 2023: $79.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $79.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $79.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $8,179.08 | 2019-2023 | Jornay Pm |
| Abbvie INC. | $708.19 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $635.72 | 2019-2022 | |
| Allergan, INC. | $434.48 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $349.79 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $270.36 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $253.97 | 2019-2022 | |
| Tris Pharma INC | $253.69 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $249.02 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $235.44 | 2019-2021 | |
| Lundbeck LLC | $221.12 | 2019-2022 | |
| Corium, LLC | $211.87 | 2021-2022 | |
| Bausch Health US, LLC | $202.93 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $132.74 | 2021-2022 | |
| Neos Therapeutics, LP | $123.68 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $123.14 | 2019 | |
| Neurocrine Biosciences, INC. | $119.42 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $95.60 | 2019-2022 | |
| Brainsway USA INC | $94.98 | 2021 | |
| Indivior INC. | $68.88 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $63.64 | 2019 | |
| Alkermes, INC. | $54.00 | 2021 | |
| Owp Pharmaceuticals, INC. | $37.47 | 2020-2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.63 | 2021 | |
| Alfasigma USA, INC. | $17.62 | 2021 | |
| Merck Sharp & Dohme LLC | $12.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.